GPER1 and neoplasm: The methylation, mutation and mutation-related prognosis of GPER1 in cancers, the associated pathways in specific cancers and its extensive correlation with immune components suggest that GPER1 may have a bright future in the diagnosis, and prognosis of multiple tumours, providing new concepts for precise and personalised anti-tumour strategies.